Frontier Pharma: Parkinsons Disease - Identifying and Commercializing First-in-Class Innovation
The report describes the key fact that the mechanism of action of most current and pipeline therapies for Parkinson’s disease is different: most current therapies focus on neuromodulatory receptors, whereas a majority of pipeline products act in a neuroprotective fashion, targeting and eliminating dysfunctional disease processes.
The report presents the clinical and commercial landscape of Parkinson’s disease, in order to deliver a clear view of the therapeutics and how they would affect the global scenario. It examines the genetic and environmental causes of Parkinson’s disease and discusses the pathophysiology of the disease.
The report details the Parkinson’s disease therapeutics market’s competitive landscape as one virtually foreign to consolidation. Of the many Parkinson’s disease therapeutics brought into the market since 2006, only nine have been developed in a collaborative effort. This is presented as a major growth opportunity for market players in the Parkinson’s disease therapeutics market, as collaboration will aid the scientific aspect of the research, helping the companies achieve more precise conclusions.
Apart from collaboration, consistent innovation is presented as a major factor that will aid competitors gain an edge in the highly fragmented market for Parkinson’s disease therapeutics. Like any field in medicine, innovation is the one sure way of advancing ahead of competitors on the back of stronger therapeutics with a more effective and more precise action. The innovation of biologic therapeutics, in particular, will be an attractive investment options, as it is a promising field and is supported by financial support from governments.
Among pipeline products, the report particularly details pipeline programs targeting the following factors: LRRK2, progranulin, glial cell-derived neurotrophic factor, cerebral dopamine neurotrophic factor, tyrosine receptor kinase B, mesencephalic astrocyte-derived neurotrophic factor, metabotropic glutamate receptor, DJ-1, C-jun-N-terminal kinases, reactive oxygen species, heat shock proteins, heat shock transcription factor, growth hormone secretagogue receptor, protein phosphasate 2A, and cytochrome P450 2D6.
Compiled by experienced industry experts, the report includes primary and secondary information detailing the trajectory of the market for Parkinson’s disease therapeutics and includes insightful inputs from leading experts.
